Roche sets sights on Novartis, Biogen as SMA trial hits target

[cafead]

via Roche's bid to rival Biogen and Novartis in treating spinal muscular atrophy (SMA) got a lift on Monday when the Swiss drugmaker said its drug risdiplam improved motor function of patients in a key study.

article source